In individuals with MCI, a combination of p-tau181, p-tau217 and Aβ42/40 ratio more accurately predicts AD conversion (AUC = 0.87 [0.82–0.92]) compared to that of any single biomarker, but it was not statistically different than a model with five blood biomarkers (p-tau181, p-tau217, Aβ42/40, NfL and APOE ε4 status) with an AUC = 0.89 [0.85–0.93] (p = 0.10) [170]. This evidence concerns the gene NEFL and Alzheimer disease.